Related Experiment Video
Updated: Apr 14, 2026
Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
Acral Lentiginous Melanoma With NRAS Mutation and Ocular Surface Toxicity Following Immunotherapy and Investigational
Elisah Huynh1,2,3, Andrew Gregory1,2, Peter Y Chang1,2
1The Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, USA.
Abstract:
We report the case of a patient with metastatic foot melanoma enrolled in a clinical trial of the anti-RAS agent RMC-6236 who developed chronic bilateral corneal epithelial defects and thinning, likely secondary to the systemic effects of targeted therapy. This case highlights the ocular surface toxicity associated with systemic anticancer therapies affecting rapidly dividing cells and the overall importance of multidisciplinary medical management of these systemic therapeutics.
Insights
A patient receiving targeted melanoma therapy developed chronic eye problems. This case highlights ocular surface toxicity from anticancer drugs and the need for multidisciplinary care.
Area of Science:
- Ophthalmology
- Oncology
- Dermatology
Background:
- Metastatic melanoma is a serious cancer.
- Targeted therapies offer new treatment options.
- Systemic therapies can cause side effects.
Purpose of the Study:
- To report a case of ocular toxicity from a novel anti-RAS agent.
- To highlight the importance of monitoring ocular surface health during cancer treatment.
Main Methods:
- Case report of a patient with metastatic foot melanoma.
- Patient received RMC-6236, an anti-RAS agent, in a clinical trial.
- Ocular surface toxicity (corneal epithelial defects and thinning) was observed.
Main Results:
- The patient developed chronic bilateral corneal epithelial defects and thinning.
- These ocular issues are likely secondary to systemic effects of the targeted therapy.
- The toxicity affected rapidly dividing cells of the ocular surface.
Conclusions:
- Systemic anticancer therapies, including targeted agents, can cause ocular surface toxicity.
- Multidisciplinary management is crucial for patients undergoing systemic cancer therapeutics.
- Close monitoring of ocular health is essential during treatment.
More Related Videos
06:09Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
06:46Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021